Oncology · NSCLC
The initiation of the Phase 1/2 study of BH-30643 by BlossomHill Therapeutics is significant as it targets a specific patient population with EGFR and/or HER2 mutations in NSCLC. The outcomes of this trial could reshape treatment paradigms and influence competitive positioning in the oncology market.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/16/2026, 12:31:19 AM
Assessment confidence: 57% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The initiation of the Phase 1/2 study of BH-30643 by BlossomHill Therapeutics is significant as it targets a specific patient population with EGFR and/or HER2 mutations in NSCLC. The outcomes of this trial could reshape treatment paradigms and influence competitive positioning in the oncology market. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 6 ranked evidence items (2 high-relevance).
The study's outcomes could influence treatment paradigms for NSCLC and inform portfolio strategies regarding targeted therapies. The strongest clinical anchor is A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (ClinicalTrials.gov), sub-indication match (her2); mechanism alignment (her2). In her2, 4 regulatory and 0 competitive items passed relevance filtering for BlossomHill Therapeutics.
The most relevant competitive pressure comes from This trial positions BH-30643 within a competitive landscape focused on targeted therapies for NSCLC, particularly in mutation-specific cohorts..
Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Regulatory pathway relevance (bla). The trial's results will be critical for regulatory submissions and could affect labeling and approval pathways for similar therapies targeting mutation-specific cohorts.
FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — ENHERTU (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (bla)
FDA document
View sourceFDA AP — HERCEPTIN HYLECTA (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (bla)
FDA document
View sourceOngoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View sourceA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View sourceAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Sub-indication match (her2); Mechanism alignment (HER2)
FDA document
View sourceStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govlow relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceA Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFollow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View sourceTesting Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View sourceNo evidence in this category.
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceSafety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe initiation of the Phase 1/2 study of BH-30643 by BlossomHill Therapeutics is significant as it targets a specific patient population with EGFR and/or HER2 mutations in NSCLC. The outcomes of this trial could reshape treatment paradigms and influence competitive positioning in the oncology market.
If successful, BH-30643 could capture market share in the targeted therapy segment for NSCLC, impacting revenue streams for competitors and altering market dynamics.
The trial's results will be critical for regulatory submissions and could affect labeling and approval pathways for similar therapies targeting mutation-specific cohorts.
Monitor the determination of the RP2D and MTD, as well as preliminary efficacy results from the Phase 2 portion of the trial.
Track for follow-up milestones; no immediate action required.